Orexo acquires exclusive US rights to commercialize vorvida®, a digital therapy for alcohol use disorder with scientifically proven efficacy
-Deal further strengthens Orexo’s partnership with GAIA -Orexo committed to digital health to address addiction Uppsala, Sweden – November 27, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, today announces it has acquired the exclusive US rights to vorvida®, a digital therapy for the treatment of Alcohol Use Disorder (AUD), from GAIA AG (GAIA), a global leader in digital therapeutics. Today’s news follows an earlier agreement with GAIA in August 2019, for the exclusive global commercial